Treating HCC with genetically modified NK-cell therapy
Blocking the TGF-β signalling pathway produced effective antitumour activity against hepatocellular carcinoma.
List view / Grid view
Blocking the TGF-β signalling pathway produced effective antitumour activity against hepatocellular carcinoma.
In this exclusive interview with Elicio Therapeutics, we explore the transformative potential of liquid biopsy in oncology drug development, particularly spotlighting its application in Elicio’s AMPLIFY-201 study of ELI-002, a promising therapeutic cancer vaccine candidate.
Understanding how MMR-deficient colorectal cancers drive tumour growth and avoid immune detection could pave the way for personalised cancer medicine.
Molecular, cellular and metabolic analyses of liver biopsies identified markers that may predict subsequent metastasis of pancreatic cancer.
The inhibitor, HVH-2930, effectively induced apoptosis in breast cancer cells without initiating the heat shock response.
A novel screening tool may increase the five-year survival rate of hepatocellular carcinoma patients to 90 percent.
Researchers have developed a 3D approach to improve the characterisation of pancreatic intraepithelial neoplasias.
Scientists discovered that, depending on germline variation, CRISPR-based experiments can result in false negatives.
The algorithm can accurately diagnose cases of lung adenocarcinoma, determining structural features that are statistically most significant for assessing disease severity and likelihood of tumour recurrence.
In this Q&A, Associate Director, Research at Immunocore, Dr Ana Pereira Ribeiro, talks about IMC-R117C, a T cell receptor bispecific immunotherapy directed towards a novel target, PIWIL1, and about to enter Phase I testing in colorectal and gastrointestinal cancers.
A new immunotherapy approach combining co-engineered T cells and antibodies enhances phagocytosis of tumour cells.
Through multi-omics analysis, researchers find that oestrogen signalling could be a target for never-smoker lung cancer cases.
In this Q&A, senior leaders at Caris Life Sciences discuss how the company is advancing precision medicine by integrating ADCs into patient-specific cancer treatment plans, focusing on novel target discovery through comprehensive molecular profiling and clinico-genomic data.
A novel drug, JHU083, turns into its active, glutamine-blocking form inside tumours, shrinking prostate and bladder cancers in mice.
Following Zymeworks’ presentation at AACR 2024, in this Q&A, Dr Nina Weisser explains how the next generation trispecific T cell engager platform with integrated CD28 costimulation is engineered to tackle solid tumours.